reports
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effe...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Am...
electroCore to Participate at the Planet MicroCap Showcase
electroCore to Participate at the Planet MicroCap Showcase ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025. Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged...
electroCore Named One of The Americas’ Fastest Growing Companies by th...
electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ Fastest Growing Companies 2025.” Debuting at number 125, electroCore joins 300 other companies dominating in their respective sectors. This is the sixth annual list that the Financial Times published, ranking companies based on the highest compound annual revenue growth between the year...
electroCore to Participate at the Needham Virtual Healthcare Conferenc...
electroCore to Participate at the Needham Virtual Healthcare Conference ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 10, 2025. Dan Goldberger, CEO and Joshua Lev, Chief Financial Officer, will host a group presentation at 2:15 p.m. ET and participate in one-on-one meetings throughout the day. DATE: April 10, 2025TIME: 2:15 p.m. ETWEBCAST: A live audio webcast...
electroCore Extends VA Contract for Five Years
electroCore Extends VA Contract for Five Years ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030. “Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a cost effective therapeutic benefiting our veter...
electroCore Announces Full Year 2024 Financial Results
electroCore Announces Full Year 2024 Financial Results Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the “Company”), a commercial-stage bioelectronic medicine Company and ...
electroCore to Announce Fourth Quarter and Full Year Ended December 31...
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025 ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Deta...
electroCore to Participate at Upcoming Investor Conferences
electroCore to Participate at Upcoming Investor Conferences Management to Attend the 37th Annual Roth Conference and the LSI USA '25 ROCKAWAY, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in two upcoming investor conferences. Management will attend and engage with investors at: The 37th Annual Roth Conference March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. Joshua Lev, Chief Financial Officer, will host one-on-...
electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Di...
electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent™ by Spark Biomedical, an FDA cleared non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities. “At Spark Biomedi...
electroCore’s Truvaga™ Now Available on Amazon®
electroCore’s Truvaga™ Now Available on Amazon® Leading Direct to Consumer Vagus Nerve Stimulator Available for Purchase on World’s Largest Retail Platform ROCKAWAY, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its flagship wellness product, , is now available for purchase on Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relie...
electroCore Expands Intellectual Property Portfolio
electroCore Expands Intellectual Property Portfolio electroCore Granted Two New U.S. Patents ROCKAWAY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received two patent issue notifications from the United States Patent and Trademark Office (USPTO). US Patent No. 12,208,263 entitled “Devices and Methods for Vagal Nerve Stimulation” was issued on January 28, 2025 and generally relates to methods for modulating the vagus nerve by positioning an electrode in contact with ...
electroCore to Participate at the BTIG MedTech, Digital Health, Life S...
electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference ROCKAWAY, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 11-12, 2025 in Snowbird, Utah. Dan Goldberger, Chief Executive Officer, will host one-on-one meetings throughout the conference. To schedule a one-on-one meeting with Mr. Goldberger, investors ...
electroCore Expands Intellectual Property Portfolio
electroCore Expands Intellectual Property Portfolio electroCore Granted Five New U.S. Patents ROCKAWAY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received five patent issue notifications from the United States Patent and Trademark Office (USPTO). The five patents have been issued between December 17, 2024, and December 31, 2024: US Patent No. 12,168,128 entitled “Systems and Methods for Treating a Medical Condition” was issued on December 17, 2024, and generally r...
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platfo...
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it ha...
electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Awa...
electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award ROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been recognized in the inaugural Woman’s World Magazine 50 over 50 Award. Products were evaluated based on quality, effectiveness, and value, with these awards honoring outstanding products for women over 50. A link to the article can be found here: Woman’s . “We are thrilled to receive the Woman’...
electroCore Donates gammaCore Sapphire for Real World Evaluation of nV...
electroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis ROCKAWAY, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has donated 20 gammaCore Sapphire D’s to be used by Dr. Robin Ely, Director of Integrative and Regenerative Medicine, a global practice focused on the development of integrated treatment regimens for neurocognitive and neurodegenerative disorders, and Dr. Yori Gidron, professor of health psychology at the Dept. of Nursing, ...
electroCore to Participate at the Canaccord Genuity MedTech, Diagnosti...
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21 ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024. Joshua Lev, Chief Financial Officer, will host one-on-one meetings throughout the day. To schedule a one-on-one meeting with Mr. Lev, inve...
electroCore Announces Third Quarter 2024 Financial Results
electroCore Announces Third Quarter 2024 Financial Results Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights Eighth consecutive record quarterly revenue of $6.6 million, an increase of 45% over third quarte...
ElectroCore’s Truvaga™ Plus Wins Men’s Health Magazine Tech Award
ElectroCore’s Truvaga™ Plus Wins Men’s Health Magazine Tech Award ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been awarded the prestigious Men’s Health Magazine Tech Award for a pioneering wellness device recognized for innovation and excellence. The award celebrates groundbreaking advancements in health and technology and highlights products that significantly impact men’s health and wellness. A link to the arti...
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(...
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company’s VP, Corporate Controller. The Compensation Committee of electroCore’s Board of Directors granted 5,000 restricted stock units (“RSUs”) to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement mat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.